Hydrallazine or phentolamine as adjuncts to beta-adrenoceptor blockade/thiazide therapy in hypertension.
Ten patients not maximally controlled on an oxprenolo/cyclopenthiazide regimen for moderately severe hypertension were treated in a double blind crossover trial with either hydrallazine (75-150 mg/day) or phentolamine (60-120 mg/day) or placebo in addition to their other therapy. Additional phentolamine therapy did not lower blood pressure significantly when compared with placebo. Additional hydrallazine (75-150 mg/day) produced an approximate 10 mm, Hg fall in diastolic blood pressure, but no significant fall in systolic blood pressure. Pulse rates did not alter with the addition of hydrallazine or phentolamine. In patients who fail to attain optimal blood pressure response to beta-adrenoceptor blocking drugs it is suggested that the addition of hydrallazine is a useful measure.
D000328:Adult; D001581:Benzothiadiazines; D002986:Clinical Trials as Topic; D004232:Diuretics; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010096:Oxprenolol / Q000627:therapeutic use; D010646:Phentolamine / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D001581:Benzothiadiazines; D004232:Diuretics; D010919:Placebos; D049993:Sodium Chloride Symporter Inhibitors; D006830:Hydralazine; D010096:Oxprenolol; D010646:Phentolamine